Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Woodland and SBH Sciences Announce New Incubator ModelWoodland and SBH Sciences Announce New Incubator Model to support IND-enabling Preclinical Efficacy Studies for Novel Oncology Molecules
The process starts with the identification of a novel molecule brought to Woodland-SBH Sciences for idea realization. This includes biological support for lead optimization and SAR studies, and pharmacological modeling starting with in vitro assays, followed by a seamless translation to in vivo state-of-the- Effective immediately, Woodland-SBH Sciences is accepting proposals for new molecule testing. Efficacy studies will culminate with an IND-enabling package ready for regulatory submission. As your study is progressed, data obtained may allow the company and the Incubator to apply for government funding or seek additional sponsorships from the venture community. The Oncology Incubator will test the new drug in a series of assays leading up to tests in primary patient tumors meant to give you a preview of the experience you will face as you move into the clinic. These preclinical trials will help to identify responder and non-responder profiles, including the identification of responder signatures or predictive biomarkers, and is intended to provide an extra measure of confidence as you move into early clinical development. Michael Briggs, PhD, President of Woodland Pharmaceuticals, said: "We will first evaluate the molecule properties, your early data and IP estate, and then take the best ideas and molecules and qualify them with in vitro assays at SBH. We then move smoothly and rapidly into Woodland for xenograft models and more complex in vivo studies, including PK and PK/PD modeling. We will draw on SBH Sciences’s expertise in making antibodies and running biomarker studies to assist with target activity marker analyses. Taking ideas and making them into drugs is what this next evolution in the development of the Woodland-SBH Sciences partnership entails." Raphael Nir, PhD President of SBH Sciences, said of becoming an incubator, "The most rapid and efficient path to the IND starts with the preclinical in vitro and animal model studies. Our aligned discovery capabilities provide complementary expertise that will streamline the development effort, enhance innovation, and reduce development time. We are constantly expanding our services and this collaboration will allow us to help our customers reach Phase I trials, primarily in oncology and inflammation. It is our privilege to work with Dr. Michael Briggs and his dedicated and knowledgeable team". Woodland-SBH Sciences as an “Oncology Incubator” • A home for your novel drug ideas and your molecules • Evaluation of your molecules against current therapies and other drugs in clinical trials • A shared risk opportunity to rapidly proceed to preclinical Proof-of-Concept • Our data packages will better Enable Grant Applications – SBIR/STTR • Our efficacy studies will provide direct confirmation of your ideas and prove that your molecules can compete in the clinic to Enable Funding Opportunities • We propel your research from a good idea to a well-characterized molecule moving assertively toward the Clinic About Woodland Oncology Services: Woodland Oncology Services provides experience and a proven history of oncology expertise in xenograft studies and in vivo capabilities including drug resistant tumor models. These skills in combination with primary patient tumor resources will bring together the different phases of the preclinical process under one virtual roof. For more information, please visit our website: www.woodlandoncologyservices.com Or follow us on LinkedIn at http://www.linkedin.com/ About SBH Sciences: SBH Sciences is known for their in vitro work in anti-cancer and anti-inflammation including cytokines and biomarkers. With over 180 Human Cancer Cells and previous experience with combination drug testing and evaluation, SBH Sciences is a key in the incubator model. The invaluable services and help from SBH Sciences have led multiple companies to reach the clinic. For a list of the companies and a link to their website, please see below. For more information, please visit: www.sbhsciences.com Or Follow us on LinkedIn http://www.linkedin.com/ Companies that have reached the clinic with the help of SBH Sciences: Neumedicines, Inc. Karyopharm Galectin Therapeutics Contact: SBH Sciences President and CSO Raphael Nir, Ph.D., 508-650-6218 x 214 rnir@sbhsciences.com Woodland Oncology Services President and CSO Michael R. Briggs, Ph.D., 617-416-2522 mbriggs@woodlandpharma.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|